Pulsante Therapy clinched Prestigious Forfait Innovation Package to advance Medical Innovation for Cluster Headache in France
Autonomic Technologies asserted that the College of the French National Authority for Health issued a optimistic opinion on Forfait Innovation package for the Pulsante SPG Microstimulator System. The award will endorse a randomized controlled Trial for patients afflicted with Cluster headache. Autonomic Technologies which is a medical device company aiming development and commercialization of innovative therapies for the treatment of acute headache.
The Forfait Innovation program was rolled out to escalate the introduction of promising medical innovation in France while simultaneously collating data to endorse and advocate a longer-term reimbursement decision. Funding is allocated only to select medical technologies that exhibit breakthrough innovation bringing remarkable Clinical benefits thereby cutting medical bills and remarkably healthcare system costs.
Professor Michel Lantéri-Minet, a neurologist at Centre Hospitalier Universitaire de Nice said “Five years after our participation in the European Pathway CH-1 study, this is an important step in allowing use of the innovative sphenopalatine ganglion stimulation system at French tertiary headache centers to treat severe cluster headache sufferers.”
The Pulsante SPG Microstimulator is a novel, miniaturized wireless device designed for patient-controlled, on-demand therapy to relieve the acute pain of cluster attacks. The miniature implant is inserted above the upper jaw in a 60- to 90-minute oral procedure that leaves no visible scar. The Pulsante SPG Microstimulator System is CE marked in Europe for the acute pain relief of cluster headache and pain relief for highly disabled migraine patients.